Back to Journals » International Journal of Nanomedicine » Volume 7

Combining the chemotherapeutic effects of epigallocatechin 3-gallate with siRNA-mediated p53 knock-down results in synergic pro-apoptotic effects

Authors Berindan-Neagoe I, Braicu C, Irimie A

Received 31 July 2012

Accepted for publication 22 August 2012

Published 12 December 2012 Volume 2012:7 Pages 6035—6047


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Ioana Berindan-Neagoe,1,2 Cornelia Braicu,1 Alexandru Irimie3,4

Department of Functional Genomics and Experimental Pathology, Cancer Institute, “Ion Chiricuta”, Cluj-Napoca, Romania; 2Department of Immunology, University of Medicine and Pharmacy, “I. Hatieganu”, Cluj-Napoca, Romania; 3Department of Surgical Oncology, University of Medicine and Pharmacy, “I. Hatieganu”, Cluj-Napoca, Romania; 4Department of Surgery, Cancer Institute, “Ion Chiricuta”, Cluj-Napoca, Romania

Abstract: Plant extracts and compounds are applied to a wide variety of diseases in which traditional drugs have proven ineffective. A quickly developing trend in biomedicine is the therapeutic use of siRNA (short interfering RNA) structures. The focus of this study was on evaluating the gene expression involved in the modulation of apoptosis, in cases of combinatorial treatment (-)-epigallocatechin-3-gallate (EGCG) and/or p53siRNA. EGCG in combination with p53siRNA exerts synergic pro-apoptotic effects that are greater than those of each agent taken individually. There is a cumulative antiproliferative effect, induced by EGCG and p53siRNA treatment, and it is mediated through the activation of a large number of pro-apoptotic genes and the inhibition of anti-apoptotic protein expression levels. p53siRNA promotes the convergence of the extrinsic and intrinsic pathways in a synergic manner with EGCG. The chemotherapeutic effects of EGCG in combination with p53siRNA therapy induced a synergic pro-apoptotic effect, indicating the potential for development of promising new anticancer therapies.

Keywords: p53siRNA, apoptosis, HeLa cells

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

The new era of nanotechnology, an alternative to change cancer treatment

Jurj A, Braicu C, Pop LA, Tomuleasa C, Gherman CD, Berindan-Neagoe I

Drug Design, Development and Therapy 2017, 11:2871-2890

Published Date: 27 September 2017

miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples

Braicu OL, Budisan L, Buiga R, Jurj A, Achimas-Cadariu P, Pop LA, Braicu C, Irimie A, Berindan-Neagoe I

OncoTargets and Therapy 2017, 10:4225-4238

Published Date: 28 August 2017

Future trends and emerging issues for nanodelivery systems in oral and oropharyngeal cancer

Irimie AI, Sonea L, Jurj A, Mehterov N, Zimta AA, Budisan L, Braicu C, Berindan-Neagoe I

International Journal of Nanomedicine 2017, 12:4593-4606

Published Date: 26 June 2017

Epigallocatechin-3-gallate suppresses cell proliferation and promotes apoptosis and autophagy in oral cancer SSC-4 cells

Irimie AI, Braicu C, Zanoaga O, Pileczki V, Gherman C, Berindan-Neagoe I, Campian RS

OncoTargets and Therapy 2015, 8:461-470

Published Date: 20 February 2015

Clinical and pathological implications of miRNA in bladder cancer

Braicu C, Cojocneanu-Petric R, Chira S, Truta A, Floares A, Petrut B, Achimas-Cadariu P, Berindan-Neagoe I

International Journal of Nanomedicine 2015, 10:791-800

Published Date: 20 January 2015

Readers of this article also read:

MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice

Pan Y, Jia T, Zhang Y, Zhang K, Zhang R, Li J, Wang L

International Journal of Nanomedicine 2012, 7:5957-5967

Published Date: 3 December 2012

Controlled gentamicin release from multi-layered electrospun nanofibrous structures of various thicknesses

Sirc J, Kubinova S, Hobzova R, Stranska D, Kozlik P, Bosakova Z, Marekova D, Holan V, Sykova E, Michalek J

International Journal of Nanomedicine 2012, 7:5315-5325

Published Date: 8 October 2012

Enhanced oral bioavailability of a sterol-loaded microemulsion formulation of Flammulina velutipes, a potential antitumor drug

Yi C, Zhong H, Tong S, Cao X, Firempong CK, Liu H, Fu M, Yang Y, Feng Y, Zhang H, Xu X, Yu J

International Journal of Nanomedicine 2012, 7:5067-5078

Published Date: 18 September 2012


Wu Q, Chu M

International Journal of Nanomedicine 2012, 7:4531-4532

Published Date: 15 August 2012

Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo

Cai L, Wang X, Wang W, Qiu N, Wen J, Duan X, Li X, Chen X, Yang L, Qian Z, Wei Y, Chen L

International Journal of Nanomedicine 2012, 7:4499-4510

Published Date: 14 August 2012

Cationized dextran nanoparticle-encapsulated CXCR4-siRNA enhanced correlation between CXCR4 expression and serum alkaline phosphatase in a mouse model of colorectal cancer

Abedini F, Hosseinkhani H, Ismail M, Domb AJ, Omar AR, Chong PP, Hong PD, Yu DS, Farber IY

International Journal of Nanomedicine 2012, 7:4159-4168

Published Date: 31 July 2012

Development of a reduction-sensitive diselenide-conjugated oligoethylenimine nanoparticulate system as a gene carrier

Cheng G, He Y, Xie L, Nie Y, He B, Zhang Z, Gu Z

International Journal of Nanomedicine 2012, 7:3991-4006

Published Date: 31 July 2012


Marusza W, Mlynarczyk G, Olszanski R, Netsvyetayeva I, Obrowski M, Iannitti T, Palmieri B

International Journal of Nanomedicine 2012, 7:4119-4120

Published Date: 27 July 2012

NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo

Harada M, Iwata C, Saito H, Ishii K, Hayashi T, Yashiro M, Hirakawa K, Miyazono K, Kato Y, Kano MR

International Journal of Nanomedicine 2012, 7:2713-2727

Published Date: 31 May 2012